Paul Workman

46.0k total citations · 3 hit papers
535 papers, 27.7k citations indexed

About

Paul Workman is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Paul Workman has authored 535 papers receiving a total of 27.7k indexed citations (citations by other indexed papers that have themselves been cited), including 370 papers in Molecular Biology, 123 papers in Oncology and 101 papers in Cancer Research. Recurrent topics in Paul Workman's work include Heat shock proteins research (107 papers), Computational Drug Discovery Methods (70 papers) and Cancer, Hypoxia, and Metabolism (62 papers). Paul Workman is often cited by papers focused on Heat shock proteins research (107 papers), Computational Drug Discovery Methods (70 papers) and Cancer, Hypoxia, and Metabolism (62 papers). Paul Workman collaborates with scholars based in United Kingdom, United States and Canada. Paul Workman's co-authors include Paul A. Clarke, Bissan Al‐Lazikani, Udai Banerji, Florence I. Raynaud, Marissa Powers, Swee Y. Sharp, Michael I. Walton, Alison Maloney, Ian Collins and Michelle D. Garrett and has published in prestigious journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Paul Workman

534 papers receiving 27.0k citations

Hit Papers

Guidelines for the welfare and use of animals in cancer r... 2010 2026 2015 2020 2010 2012 2012 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Guidelines for the welfare and use of animals in cancer research
    2010 1.1k citations Paul Workman, Eric O. Aboagye et al. profile →
  2. Combinatorial drug therapy for cancer in the post-genomic era
    2012 766 citations Udai Banerji, Paul Workman et al. profile →
  3. Discovery of small molecule cancer drugs: Successes, challenges and opportunities
    2012 438 citations Swen Hoelder, Paul A. Clarke et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Paul Workman United Kingdom 85 18.6k 5.8k 4.4k 2.7k 2.6k 535 27.7k
Edward A. Sausville United States 92 19.3k 1.0× 11.7k 2.0× 3.4k 0.8× 2.7k 1.0× 1.0k 0.4× 329 30.9k
Steven A. Carr United States 108 31.7k 1.7× 5.4k 0.9× 4.0k 0.9× 2.1k 0.8× 1.5k 0.6× 372 44.4k
Ting‐Chao Chou United States 60 14.1k 0.8× 8.1k 1.4× 2.2k 0.5× 4.2k 1.5× 1.2k 0.5× 350 29.3k
Stephen W. Fesik United States 86 24.8k 1.3× 5.3k 0.9× 2.5k 0.6× 3.1k 1.1× 2.7k 1.0× 267 31.1k
Richard Marais United Kingdom 77 18.6k 1.0× 9.1k 1.6× 3.3k 0.8× 1.4k 0.5× 1.9k 0.7× 229 25.7k
Nathanael S. Gray United States 104 30.5k 1.6× 10.9k 1.9× 3.0k 0.7× 5.0k 1.8× 2.3k 0.9× 476 42.2k
Shaomeng Wang United States 91 20.8k 1.1× 7.0k 1.2× 1.9k 0.4× 5.4k 2.0× 4.6k 1.8× 459 29.3k
Len Neckers United States 85 19.4k 1.0× 3.1k 0.5× 3.0k 0.7× 644 0.2× 1.8k 0.7× 248 24.9k
Stefan Knapp Germany 91 21.6k 1.2× 5.6k 1.0× 1.1k 0.3× 3.7k 1.3× 2.1k 0.8× 516 29.0k
Doriano Fabbro Switzerland 74 12.4k 0.7× 3.7k 0.6× 1.4k 0.3× 1.8k 0.6× 968 0.4× 223 20.3k

Countries citing papers authored by Paul Workman

Since Specialization
Citations

This map shows the geographic impact of Paul Workman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Workman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Workman more than expected).

Fields of papers citing papers by Paul Workman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Workman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Workman. The network helps show where Paul Workman may publish in the future.

Co-authorship network of co-authors of Paul Workman

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Workman. A scholar is included among the top collaborators of Paul Workman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Workman. Paul Workman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ang, Joo Ern, Ákos Pál, Yasmin J. Asad, et al.. (2017). Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma. Molecular Cancer Therapeutics. 16(10). 2315–2323. 8 indexed citations
2.
Delgado‐Goñi, Teresa, Harold G. Parkes, Richard Marais, et al.. (2016). The BRAF Inhibitor Vemurafenib Activates Mitochondrial Metabolism and Inhibits Hyperpolarized Pyruvate–Lactate Exchange in BRAF-Mutant Human Melanoma Cells. Molecular Cancer Therapeutics. 15(12). 2987–2999. 44 indexed citations
3.
Gurden, Mark D., Isaac M. Westwood, Amir Faisal, et al.. (2015). Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance. Cancer Research. 75(16). 3340–3354. 24 indexed citations
4.
Eykyn, Thomas R., et al.. (2013). MEK1/2 Inhibition Decreases Lactate in BRAF-Driven Human Cancer Cells. Cancer Research. 73(13). 4039–4049. 42 indexed citations
5.
Bjerke, Lynn, Alan Mackay, Meera Nandhabalan, et al.. (2013). Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN. Cancer Discovery. 3(5). 512–519. 226 indexed citations
6.
Carden, Craig P., Adam Stewart, Emma Kipps, et al.. (2012). The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer. Molecular Cancer Therapeutics. 11(7). 1609–1617. 81 indexed citations
7.
Pacey, Simon, Richard H. Wilson, Mike Walton, et al.. (2011). A Phase I Study of the Heat Shock Protein 90 Inhibitor Alvespimycin (17-DMAG) Given Intravenously to Patients with Advanced Solid Tumors. Clinical Cancer Research. 17(6). 1561–1570. 154 indexed citations
8.
Faisal, Amir, Vassilios Bavetsias, Chongbo Sun, et al.. (2011). The Aurora Kinase Inhibitor CCT137690 Downregulates MYCN and Sensitizes MYCN -Amplified Neuroblastoma In Vivo. Molecular Cancer Therapeutics. 10(11). 2115–2123. 67 indexed citations
9.
Ewan, Kenneth, Bożena Pająk, Mark Stubbs, et al.. (2010). A Useful Approach to Identify Novel Small-Molecule Inhibitors of Wnt-Dependent Transcription. Cancer Research. 70(14). 5963–5973. 86 indexed citations
10.
Workman, Paul, Paul A. Clarke, Florence I. Raynaud, & Rob L. M. van Montfort. (2010). Drugging the PI3 Kinome: From Chemical Tools to Drugs in the Clinic. Cancer Research. 70(6). 2146–2157. 211 indexed citations
11.
Yap, Timothy A., Mike I. Walton, Melanie Valenti, et al.. (2010). Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930. Molecular Cancer Therapeutics. 10(2). 360–371. 59 indexed citations
12.
Al-Saffar, Nada M.S., L. Elizabeth Jackson, Florence I. Raynaud, et al.. (2010). The Phosphoinositide 3-Kinase Inhibitor PI-103 Downregulates Choline Kinase α Leading to Phosphocholine and Total Choline Decrease Detected by Magnetic Resonance Spectroscopy. Cancer Research. 70(13). 5507–5517. 54 indexed citations
13.
Gaspar, Nathalie, Swee Y. Sharp, Suzanne A. Eccles, et al.. (2010). Mechanistic Evaluation of the Novel HSP90 Inhibitor NVP-AUY922 in Adult and Pediatric Glioblastoma. Molecular Cancer Therapeutics. 9(5). 1219–1233. 62 indexed citations
14.
Baird, Richard D., Jos Kitzen, Paul A. Clarke, et al.. (2009). Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors. Molecular Cancer Therapeutics. 8(6). 1430–1437. 33 indexed citations
15.
Bax, Dorine A., Nathalie Gaspar, Suzanne E. Little, et al.. (2009). EGFRvIII Deletion Mutations in Pediatric High-Grade Glioma and Response to Targeted Therapy in Pediatric Glioma Cell Lines. Clinical Cancer Research. 15(18). 5753–5761. 71 indexed citations
16.
Gaspar, Nathalie, Swee Y. Sharp, Simon Pacey, et al.. (2009). Acquired Resistance to 17-Allylamino-17-Demethoxygeldanamycin (17-AAG, Tanespimycin) in Glioblastoma Cells. Cancer Research. 69(5). 1966–1975. 92 indexed citations
17.
18.
Leyton, Julius, Graham Smith, Meg Perumal, et al.. (2008). Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901. Molecular Cancer Therapeutics. 7(9). 3112–3121. 41 indexed citations
19.
Williamson, Daniel, Joanna Selfe, Tony Gordon, et al.. (2007). Role for Amplification and Expression of Glypican-5 in Rhabdomyosarcoma. Cancer Research. 67(1). 57–65. 77 indexed citations
20.
Banerji, Udai, Michael I. Walton, Florence I. Raynaud, et al.. (2005). Pharmacokinetic-Pharmacodynamic Relationships for the Heat Shock Protein 90 Molecular Chaperone Inhibitor 17-Allylamino, 17-Demethoxygeldanamycin in Human Ovarian Cancer Xenograft Models. Clinical Cancer Research. 11(19). 7023–7032. 126 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Edward A. Sausville Breakdown of academic impact, for papers by Steven A. Carr Breakdown of academic impact, for papers by Ting‐Chao Chou Breakdown of academic impact, for papers by Stephen W. Fesik Breakdown of academic impact, for papers by Richard Marais Breakdown of academic impact, for papers by Nathanael S. Gray Breakdown of academic impact, for papers by Shaomeng Wang Breakdown of academic impact, for papers by Len Neckers Breakdown of academic impact, for papers by Stefan Knapp Breakdown of academic impact, for papers by Doriano Fabbro
Rankless by CCL
2026